Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Lanzoni
  NCT04355728		 RCTstem cellsplaceboCOVID 19 hospitalizedsome concern
12/12 suggested
  • suggested 86 % decrease in death D28 with a moderate degree of certainty due to some concern in risk of bias
  • suggested 89 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
Lopes MIF
  RBR-8jyhxh		 RCTcolchicineplaceboCOVID 19 hospitalizedhigh
19/19 inconclusive
    Salehzadeh
          IRCT20200418047126N1    		 RCTcolchicineplaceboCOVID 19 hospitalizedsome concern
    		50/50 inconclusive
      Comparing two groups showed significantly different only in the duration of hospitalized (P<0.05). Although in colchicine group dyspnea was improved more rapid than the placebo group, but it was not meaningful.

      COVID-19 severe or critically meta-analysis

      COLCHIVID
              NCT04367168      		 RCTcolchicineplaceboCOVID-19 severe or criticallyNA
      		66/60 inconclusive
      • inconclusive 17 % decrease in death or transfer to ICU (PE)
      Shi
              NCT04288102      		 RCTstem cellsplaceboCOVID-19 severe or criticallysome concern
      		66/35 inconclusive

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons